Meeting
2022 ASCO Annual Meeting
Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC).
Authors
Mohamed E. Salem
Levine Cancer Institute, Atrium Health, Charlotte, NC
Mohamed E. Salem , Thierry Andre , Sherif Mohamed El-Refai , Scott Kopetz , Josep Tabernero , Frank A. Sinicrope , Jeanne Tie , Thomas J. George , Eric VanCutsem , Elizabeth Mauer , Sara Lonardi , Michael J. Overman , David Foureau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3067)
DOI
10.1200/JCO.2022.40.16_suppl.3067
Abstract #
3067
Poster Bd #
59
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Molecular comparison of primary colorectal cancer (pCRC) with peritoneal metastases (PM).
First Author: Matthew K Stein
Poster
2021 ASCO Annual Meeting
Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.
First Author: Emil Lou
First Author: Sandra Algaze
Poster
2022 ASCO Annual Meeting
Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers.
First Author: Mohamed E. Salem